LAVA Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
LAVA Therapeutics has a total shareholder equity of $42.9M and total debt of $5.4M, which brings its debt-to-equity ratio to 12.6%. Its total assets and total liabilities are $92.3M and $49.4M respectively.
Key information
12.6%
Debt to equity ratio
US$5.38m
Debt
| Interest coverage ratio | n/a |
| Cash | US$86.80m |
| Equity | US$42.88m |
| Total liabilities | US$49.41m |
| Total assets | US$92.28m |
Recent financial health updates
Recent updates
Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive
Jun 02
LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry?
Mar 01LAVA Therapeutics: Assessing A Promising Innovator
Oct 18LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.30, revenue of $0.47M beats by $0.11M
Sep 13Financial Position Analysis
Short Term Liabilities: LVTX's short term assets ($90.2M) exceed its short term liabilities ($14.1M).
Long Term Liabilities: LVTX's short term assets ($90.2M) exceed its long term liabilities ($35.3M).
Debt to Equity History and Analysis
Debt Level: LVTX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if LVTX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LVTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: LVTX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 4.6% each year.